Recent Updates
Recently added Catalysts

LY3200882

Phase 1

Healthy | Small molecule | Other |Eli Lilly and Company|Last Updated: Mar 8, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment23
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03792139An Interaction Study of LY3200882 in Healthy ParticipantsPHASE1 COMPLETED 23 — — Jan 8, 2019Feb 23, 2019Mar 8, 20191 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3200882
Baseline through 72 hours post-dose

PK: Cmax of LY3200882

PK: Area Under the Concentration Curve (AUC) of LY3200882
Baseline through 72 hours post-dose

PK: AUC of LY3200882

Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
LY3200882EXPERIMENTALLY3200882 administered orally.
Itraconazole + LY3200882EXPERIMENTALItraconazole + LY3200882 administered orally.
Interventions
NameTypeDescription
LY3200882DRUGAdministered orally.
ItraconazoleDRUGAdministered orally.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy males or postmenopausal females, as determined by medical history and physical examination Exclusion Criteria: * Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable o...

Countries:United States
Unlock Eligibility Criteria